Pfiz­er buys in­to de­cen­tral­ized co­op­er­a­tive to ac­cel­er­ate R&D in hu­man longevi­ty

The biggest of Big Phar­ma is turn­ing over a new, edgi­er leaf, propos­ing to spend $500,000 to join a new co­op­er­a­tive, known as Vi­taDAO, for com­mu­ni­ty-gov­erned and de­cen­tral­ized drug de­vel­op­ment fo­cused on ex­tend­ing hu­man life.

The co­op­er­a­tive aims to bet­ter align var­i­ous forms of ear­ly-stage fund­ing in longevi­ty bio­phar­ma through a com­bo of nov­el and buzz­word-heavy frame­works like de­cen­tral­ized au­tonomous or­ga­ni­za­tions, non-fun­gi­ble to­kens, and fi­nan­cial en­gi­neer­ing tools that run on the Ethereum blockchain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER